We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+3.95%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
-$38.6M
(-12%)
Cap. Flow
-$43.3M
Cap. Flow
% of AUM
-15.88%
Top 10 Holdings %
Top 10 Hldgs %
53.77%
Holding
41
New
13
Increased
7
Reduced
11
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$13.1M |
| 2 |
AbbVie
ABBV
|
+$12.9M |
| 3 |
Medtronic
MDT
|
+$10.7M |
| 4 |
Johnson & Johnson
JNJ
|
+$10.4M |
| 5 |
ACOR
Acorda Therapeutics
ACOR
|
+$8.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$20.4M |
| 2 |
MON
Monsanto Co
MON
|
+$18.4M |
| 3 |
ATHN
Athenahealth, Inc.
ATHN
|
+$13.1M |
| 4 |
Insulet
PODD
|
+$12.8M |
| 5 |
DexCom
DXCM
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.56% |
| 2 | Industrials | 0% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$26.2B
| $21.6M | 7.91% |
244,073
+77,348
| +46% | +$7.44M |
|
2
Eli Lilly
LLY
$1.03T
| $19.3M | 7.08% |
310,917
+42,830
| +16% | +$2.56M |
|
|
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $16.4M | 6.01% |
204,882
+22,916
| +13% | +$1.66M |
|
|
4
DexCom
DXCM
$28.8B
| $15.8M | 5.77% |
1,589,060
-1,206,280
| -43% | -$10.7M |
|
|
5
Cencora
COR
$60.7B
| $13.9M | 5.1% |
+191,670
| New | +$13.1M |
|
|
6
AbbVie
ABBV
$455B
| $13.9M | 5.09% |
+245,901
| New | +$12.9M |
|
7
CALL
Zoetis
ZTS
$31.9B
| $12.3M | 4.49% |
+380,000
| New | +$11.7M |
|
8
HCA Healthcare
HCA
$85.7B
| $11.6M | 4.24% |
205,055
+11,829
| +6% | +$624K |
|
|
9
Medtronic
MDT
$110B
| $11.2M | 4.11% |
+175,824
| New | +$10.7M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.8M | 3.97% |
69,249
-4,862
| -7% | -$768K |
|
|
11
Johnson & Johnson
JNJ
$617B
| $10.8M | 3.94% |
+102,768
| New | +$10.4M |
|
12
Universal Health Services
UHS
$9.88B
| $10.7M | 3.93% |
111,887
-11,872
| -10% | -$1.03M |
|
13
Accuray
ARAY
$33.9M
| $9.7M | 3.56% |
1,102,494
+415,925
| +61% | +$3.6M |
|
|
ZLTQ
14
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $9.53M | 3.49% |
627,523
+41,458
| +7% | +$709K |
|
15
Encompass Health
EHC
$11B
| $8.55M | 3.13% |
299,617
+57,470
| +24% | +$1.6M |
|
16
Perrigo
PRGO
$1.43B
| $8.1M | 2.97% |
+55,554
| New | +$7.87M |
|
|
ACOR
17
DELISTED
Acorda Therapeutics
ACOR
| $7.98M | 2.92% |
+1,973
| New | +$8.05M |
|
18
Biogen
BIIB
$30.7B
| $7.93M | 2.91% |
25,161
-11,815
| -32% | -$3.56M |
|
|
MGLN
19
DELISTED
Magellan Health Services, Inc.
MGLN
| $7.92M | 2.9% |
+127,180
| New | +$7.47M |
|
|
ITMN
20
DELISTED
INTERMUNE INC
ITMN
| $7.75M | 2.84% |
+175,422
| New | +$6.46M |
|
|
AEGR
21
DELISTED
Aegerion Pharmaceuticals
AEGR
| $6.39M | 2.34% |
+199,037
| New | +$7.41M |
|
|
UAM
22
DELISTED
Universal American Corp
UAM
| $5.71M | 2.09% |
+686,000
| New | +$5.2M |
|
|
23
Zoetis
ZTS
$31.9B
| $5.58M | 2.05% |
173,034
-187,727
| -52% | -$5.76M |
|
|
AGN
24
DELISTED
Allergan Inc
AGN
| $5.47M | 2.01% |
32,336
-64,291
| -67% | -$10M |
|
25
Tandem Diabetes Care
TNDM
$1.3B
| $3.48M | 1.28% |
21,425
-15,401
| -42% | -$2.62M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, March Altus Capital Management held 41 positions worth $273M, down 12% from $311M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
March Altus Capital Management withdrew a net $43.3M in Q2 2014, closing 10 positions and reducing 11 holdings. Its most notable exit was Alkermes, an estimated $20.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Industrials and Materials.
Against the trend, March Altus Capital Management opened a new position in Cencora worth $13.9M.
- March Altus Capital Management's largest Q2 2014 buy was Cencora: 191,670 shares worth $13.9M.
- March Altus Capital Management added most to United Therapeutics in Q2 2014, an estimated $7.44M increase.
- March Altus Capital Management's biggest Q2 2014 reduction was DexCom, cutting an estimated $10.7M.
- March Altus Capital Management fully exited Alkermes in Q2 2014, selling an estimated $20.4M.
- March Altus Capital Management's ten largest holdings make up 54% of its $273M portfolio in Q2 2014.
- March Altus Capital Management opened 13 new positions and closed 10 in Q2 2014.
- March Altus Capital Management's portfolio value fell 12% quarter-over-quarter to $273M.
Based on March Altus Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.